Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL.

Nat Med. 2012 Jan 8;18(2):281-5. doi: 10.1038/nm.2581.

2.

Entry of hepatitis C virus into the cell: a therapeutic target.

Del Campo JA, Rojas Á, Romero-Gómez M.

World J Gastroenterol. 2012 Sep 7;18(33):4481-5. doi: 10.3748/wjg.v18.i33.4481.

3.

Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe.

Monrroy H, López-Lastra M, Soza A.

Med Hypotheses. 2017 May;102:51-55. doi: 10.1016/j.mehy.2017.03.016. Epub 2017 Mar 9.

PMID:
28478831
4.

Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver.

Tang W, Jia L, Ma Y, Xie P, Haywood J, Dawson PA, Li J, Yu L.

Biochim Biophys Acta. 2011 Sep;1811(9):549-55. doi: 10.1016/j.bbalip.2011.05.013. Epub 2011 Jun 12.

5.

Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine.

Xie C, Zhou ZS, Li N, Bian Y, Wang YJ, Wang LJ, Li BL, Song BL.

J Lipid Res. 2012 Oct;53(10):2092-101. Epub 2012 Jul 17.

6.

The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.

Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, Li BL, Song BL.

Cell Metab. 2008 Jun;7(6):508-19. doi: 10.1016/j.cmet.2008.04.001.

7.

Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice.

Xie P, Jia L, Ma Y, Ou J, Miao H, Wang N, Guo F, Yazdanyar A, Jiang XC, Yu L.

Arterioscler Thromb Vasc Biol. 2013 May;33(5):920-5. doi: 10.1161/ATVBAHA.112.301187. Epub 2013 Mar 7.

8.

Flotillins play an essential role in Niemann-Pick C1-like 1-mediated cholesterol uptake.

Ge L, Qi W, Wang LJ, Miao HH, Qu YX, Li BL, Song BL.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):551-6. doi: 10.1073/pnas.1014434108. Epub 2010 Dec 27.

9.

Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane.

Knöpfel M, Davies JP, Duong PT, Kvaernø L, Carreira EM, Phillips MC, Ioannou YA, Hauser H.

Biochim Biophys Acta. 2007 Sep;1771(9):1140-7. Epub 2007 Jun 23.

PMID:
17689140
10.

Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells.

Yamanashi Y, Takada T, Suzuki H.

J Pharmacol Exp Ther. 2007 Feb;320(2):559-64. Epub 2006 Nov 29.

11.

In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.

Hawes BE, O'neill KA, Yao X, Crona JH, Davis HR Jr, Graziano MP, Altmann SW.

Mol Pharmacol. 2007 Jan;71(1):19-29. Epub 2006 Sep 27.

12.

Niemann-pick C1-like 1 mediates alpha-tocopherol transport.

Narushima K, Takada T, Yamanashi Y, Suzuki H.

Mol Pharmacol. 2008 Jul;74(1):42-9. doi: 10.1124/mol.107.043034. Epub 2008 Apr 10.

13.

Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles.

Labonté ED, Howles PN, Granholm NA, Rojas JC, Davies JP, Ioannou YA, Hui DY.

Biochim Biophys Acta. 2007 Sep;1771(9):1132-9. Epub 2007 Mar 16.

14.

Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus.

Chamoun-Emanuelli AM, Pécheur EI, Chen Z.

Antiviral Res. 2014 Sep;109:141-8. doi: 10.1016/j.antiviral.2014.06.014. Epub 2014 Jul 11.

PMID:
25019406
15.

Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.

Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E.

Gut. 2014 Jul;63(7):1137-49.

PMID:
23903236
16.

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132-7. Epub 2005 May 31.

17.

Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1).

Davis HR Jr, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW.

Atheroscler Suppl. 2008 Sep;9(2):77-81. doi: 10.1016/j.atherosclerosissup.2008.05.008. Epub 2008 Jun 27. Review.

PMID:
18585981
18.

NPC1L1 and cholesterol transport.

Betters JL, Yu L.

FEBS Lett. 2010 Jul 2;584(13):2740-7. doi: 10.1016/j.febslet.2010.03.030. Epub 2010 Mar 19. Review.

19.

Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy.

Cao L, Chen J, Wang Y, Yang Y, Qing J, Rao Z, Chen X, Lou Z.

Protein Cell. 2018 Mar 14. doi: 10.1007/s13238-018-0521-z. [Epub ahead of print]

PMID:
29542010
20.

Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection.

Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W, Guérin M, Bourgine M, Michel ML, Lavillette D, Roingeard P, le Goff W, Budkowska A.

PLoS One. 2014 Mar 19;9(3):e92140. doi: 10.1371/journal.pone.0092140. eCollection 2014.

Supplemental Content

Support Center